Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF

Rungroj Krittayaphong1, Arjbordin Winijkul1, Rapeephon Kunjara-Na-Ayudhya2

  • 1From the Division of Cardiology, Siriraj Hospital (R.K.,A.W.), Mahidol University, Bangkok, Thailand.

Stroke
|May 12, 2020
PubMed

Insights

Guideline adherence in oral anticoagulant (OAC) management for nonvalvular atrial fibrillation patients in Thailand improves outcomes. Undertreatment or overtreatment increases risks of stroke, bleeding, and death compared to guideline-adherent care.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Oral anticoagulant (OAC) management in nonvalvular atrial fibrillation (NVAF) is crucial for improving patient outcomes.
  • Limited data exist on guideline adherence for OAC in Asian populations, particularly in Thailand.

Purpose of the Study:

  • To investigate clinical outcomes in Thai NVAF patients based on adherence to OAC management guidelines.
  • To compare outcomes between guideline-adherent, undertreated, and overtreated OAC patient groups.

Main Methods:

  • Prospective enrollment of 3327 NVAF patients from 27 hospitals in Thailand, contributing to the COOL-AF Registry.
  • Categorization into guideline adherence, undertreatment (OAC withheld in high/intermediate risk), and overtreatment (OAC in low risk or combined with antiplatelets without indication) groups.
  • Analysis of ischemic stroke, major bleeding, all bleeding, and death rates across the defined patient groups.

Main Results:

  • Guideline adherence was observed in 68.1% of patients (n=2267), undertreatment in 18.8% (n=624), and overtreatment in 13.1% (n=436).
  • Undertreated patients showed significantly higher risks of ischemic stroke and death compared to guideline-adherent patients.
  • Overtreated patients experienced increased risks of bleeding and death relative to guideline-managed patients.

Conclusions:

  • Adherence to OAC management guidelines is associated with improved clinical outcomes in Asian NVAF patients.
  • Both OAC undertreatment and overtreatment in NVAF are linked to increased adverse events compared to guideline-adherent management.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
528
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
209
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
261
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
161